IN BRIEF: ValiRx subsidiary to supply cell-based assays to OncoBone

Archived article

Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.

ValiRx PLC - Essex, England-based life science company focused on early-stage cancer therapeutics and women’s health - Says subsidiary Inaphaea Biolabs Ltd enters agreement with OncoBone Ltd. Says OncoBone clients will be able to access Inaphaea services. Notes Inaphaea is now confirmed as a cell-based assay supplier to OncoBone. Adds Inaphaea’s services are now listed on scientist.com, a database website used by biotechnology and pharmaceutical companies.

Current stock price: 8.04 pence, down 0.7%

12-month change: down 59%

Copyright 2023 Alliance News Ltd. All Rights Reserved.